For the validation set of tumor samples from 19 independent NSCLC patients (Supplementary Data 5a), we could observe a significantly lower abundance of CD8+ and CD103+CD8+ T cells in EGFR-MT compared with EGFR-WT (Fig. 4j and Supplementary Fig. S12, Supplementary Data 4c). This evidence concerns the gene CD8A and non-small cell lung carcinoma.